Cardiovascular risk reduction - quality prescribing guidance 2026-2029: consultation
Cardiovascular disease (CVD) is largely preventable, and many modifiable risk factors increase the likelihood of developing CVD. This guide highlights how to support people in modifying risk factors such as diet, healthy weight, alcohol, physical activity, stress and tobacco smoking.
Open
53 days to respond
Respond online
Glossary of Terms
The following terms are used in this consultation:
ABPM Ambulatory Blood Pressure Monitoring
ACE Angiotensin Converting Enzyme
ACR Albumin-to-Creatinine Ratio
ADR Adverse Drug Reaction
AF Atrial Fibrillation
AKI Acute Kidney Injury
ALP Alkaline Phosphatase
ALT Alanine Aminotransferase
ARB Angiotensin II Receptor Antagonist
ASCVD Atherosclerotic Cardiovascular Disease
ASSIGN ASsessing cardiovascular risk using SIGN guidelines to assign preventive treatment
AST Aspartate Aminotransferase
BIHS British and Irish Hypertension Society
BMI Body Mass Index
BMS British Menopause Society
BNF British National Formulary
BP Blood Pressure
BRAN Benefits, Risks, Alternatives, Nothing
CHA2DS2-VASc Score for Atrial Fibrillation Stroke Risk
CHD Coronary Heart Disease
CK Creatine Kinase
CKD Chronic Kidney Disease
CKD eGFR Chronic Kidney Disease Estimated Glomerular Filtration Rate
CV Cardiovascular
CVD Cardiovascular Disease
DBP Diastolic Blood Pressure
DKA Diabetic Ketoacidosis
DPP-4 Dipeptidyl Peptidase 4
ECG Electrocardiogram
eGFR Estimated Glomerular Filtration Rate
EMIS Egton Medical Information Systems – a clinical IT system
FH Familial hypercholesterolaemia
g Gram (unit of measurement)
GGT Gamma-Glutamyl Transferase
GIP Glucose-dependent Insulinotropic Polypeptide
GIP-RA Glucose-dependent Insulinotropic Polypeptide Receptor Agonists
GLP-1 Glucagon-Like Peptide-1
GLP-1RA Glucagon-Like Peptide-1 Receptor Agonists
GP General Practitioner
HbA1C Glycated Haemoglobin
HBPM Home Blood Pressure Monitoring
HCC Hepatocellular Carcinoma
HCP Healthcare Professionals
HDL High-density Lipoprotein
HDL-C High-Density Lipoprotein Cholesterol
HF Heart Failure
HMUD Hospital Medicines Utilisation Database
HRT Hormone Replacement Therapy
HSCP Health and Social Care Partnership
IHD Ischaemic Heart Disease
Kcal Kilocalorie
kg/m2 Kilograms per square Metre
LDL Low-density Lipoprotein
LDL-C Low-Density Lipoprotein Cholesterol
LFTs Liver Function Tests
LVSD Left Ventricular Systolic Dysfunction
MASLD Metabolic dysfunction-Associated Steatotic Liver Disease
mg Milligram (unit of measurement)
MHRA Medicines and Healthcare products Regulatory Agency
MI Myocardial Infarction
mmHg millimetres of Mercury (measurement for blood pressure)
ml/min millilitres per minute
mmol/L millimoles per litre
mmol/mol millimoles per mole
NAFLD Non-Alcoholic Fatty Liver Disease
NAION Non-arteritic Anterior Ischaemic Optic Neuropathy
NG NICE Guideline
NHS National Health Service
NICE The National Institute for Health and Care Excellence
NNH Number Needed to Harm
NNT Number Needed to Treat
NRT Nicotine Replacement Therapy
NSAID Non-Steroidal Anti-Inflammatory Drugs
NTI National Therapeutic Indicator
NVP Nicotine Vapour Products
OGTT Oral Glucose Tolerance Test
OHS Obesity Hypoventilation Syndrome
OSA Obstructive Sleep Apnoea
PCOS Polycystic Ovary Syndrome
PCSK9 Proprotein Convertase Subtilisin/Kexin type 9
PGD Patient Group Direction
PHS Public Health Scotland
PVD Peripheral Vascular Disease
QRISK an online medical algorithm used to estimate an individual's percentage chance of developing cardiovascular disease (such as a heart attack or stroke) within the next 10 years
QYW Quit Your Way
SADMAN Acronym used for medicine types included in medicine sick day guidance
SBP Systolic Blood Pressure
SGLT-2 Sodium-Glucose Co-Transporter 2
SGLT-2i Sodium-Glucose Co-Transporter 2 inhibitor
SELECT SELECT trial - Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity - SELECT
SHAAP Scottish Health Action on Alcohol
SIGN Scottish Intercollegiate Guidelines Network
SIMD Scottish Index of Multiple Deprivation
SLWG Short Life Working Group
SMART Specific, Measurable, Achievable, Relevant and Time-bound
SMC Scottish Medicines Consortium
SPC Summary of Product Characteristics
STU Scottish Therapeutics Utility
SUMMIT SUMMIT trial - Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity
T2D Type 2 Diabetes
TIA Transient Ischemic Attack
U&E Urea & Electrolyte Profile
U/L Units per Litre
ULN Upper Limit of Normal
UK United Kingdom
V2.0 Version 2.0
WHO World Health Organisation
Contact
Email: EPandT@gov.scot